Correspondence 0001654954-23-002715 from Dermata Therapeutics, Inc. (DRMA)
Dermata Therapeutics, Inc.
Date: March 13, 2023 · CIK: 0001853816 · Accession: 0001654954-23-002715
AI Filing Summary & Sentiment
File numbers found in text: 333-270195
Letter
Re:
drma_corresp.htmMarch 13, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Dermata Therapeutics, Inc. (the “Company”)
Registration Statement on Form S-1 (File No. 333-270195)
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission at 1:00 p.m., Eastern Time, on March 14, 2023, or as soon as practicable thereafter.
Please call Steven M. Skolnick of Lowenstein Sandler LLP at (646) 414-6947 to confirm the effectiveness of the Registration Statement or with any questions.
Very truly yours,
DERMATA THERAPEUTICS, Inc.
Show Raw Text
CORRESP
1
filename1.htm
drma_corresp.htmMarch 13, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re:
Dermata Therapeutics, Inc. (the “Company”)
Registration Statement on Form S-1 (File No. 333-270195)
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission at 1:00 p.m., Eastern Time, on March 14, 2023, or as soon as practicable thereafter.
Please call Steven M. Skolnick of Lowenstein Sandler LLP at (646) 414-6947 to confirm the effectiveness of the Registration Statement or with any questions.
Very truly yours,
DERMATA THERAPEUTICS, Inc.
By: /s/ Gerald T. Proehl
Name:
Gerald T. Proehl
Title: Chief Executive Officer